Driven by sustained growth in Somatuline and ramp-up in demand for recently-launched oncology drugs, Cabometyx and Onivyde, Ipsen started FY18 on a promising note (+23.1% at CER). We anticipate the robust growth momentum to continue and thus upgrade our target price by c.2%.
27 Apr 2018
Strong start to the year driven by oncology
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong start to the year driven by oncology
Ipsen SA (IPN:WBO) | 0 0 5.0% | Mkt Cap: 10,144m
- Published:
27 Apr 2018 -
Author:
Sumit Sayal -
Pages:
3
Driven by sustained growth in Somatuline and ramp-up in demand for recently-launched oncology drugs, Cabometyx and Onivyde, Ipsen started FY18 on a promising note (+23.1% at CER). We anticipate the robust growth momentum to continue and thus upgrade our target price by c.2%.